Premium
Activation of formyl peptide receptors induces relaxation and reduces contraction in resistance arteries
Author(s) -
Wenceslau Camilla Ferreira,
McCarthy Cameron G.,
Goulopoulou Styliani,
Webb R. Clinton
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.1131.11
Subject(s) - agonist , phenylephrine , receptor , endocrinology , medicine , contraction (grammar) , mesenteric arteries , chemistry , acetylcholine , vasodilation , biology , artery , blood pressure
Mitochondrial damage‐associated molecular patterns (DAMPs) are endogenous molecules that are released from damaged and dying cells. The innate immune system responds to cellular damage by recognizing DAMPs. One mitochondrial DAMP is formyl peptides (fMLP) that act on formyl peptide receptors (FPR). FPR 1 and 2 are expressed on neutrophils as well as in vascular cells, and promote inflammatory responses. We hypothesized that activation of both receptors increases vascular contractile response. We used mesenteric resistance arteries from 12 weeks old male Wistar rats to assess vascular function. A single dose of fMLP, FPR‐1 agonist (10 or 30μM) and a concentration response curve of lipoxin A4, FPR‐2 agonist (LXA4, 1–300nM) induced relaxation (~30%). Cyclosporine H (FRP‐1 antagonist: CsH, 1μM) inhibited the fMLP response. Also, concentration response curves to acetylcholine (ACh, 0.1nM‐30μM) and phenylephrine (PE, 1nM‐30μM) were performed in the absence or presence of CsH (1 μM), fMLP (10μM) or LXA4 (1nM). Results indicated that fMLP, but not CsH or LXA4, decreased PE contraction [Emax(%KCl), vehicle: 119±6 vs. fMLP: 96±1, p<0.05], however ACh‐induced relaxation was not altered. These data suggest that FPRs have a functional role in resistance arteries and may contribute to vascular dysfunction in pathologies associated with tissue damage such as sepsis or hypertension. Support: NIH; CNPq; SWHR